Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Oncolytic virus Stories

2013-11-27 23:04:25

Alliance for Cancer Gene Therapy (ACGT) – a Stamford, CT-based non-profit devoted exclusively to treating and eradicating cancer with cell and gene therapies – has provided a $500,000 grant to combat glioblastoma, one of the most difficult types of brain cancer to treat. Visit http://www.ACGTFoundation.org. United States and Canada (PRWEB) November 27, 2013 Alliance for Cancer Gene Therapy (ACGT) – a Stamford, CT-based non-profit devoted exclusively to treating and eradicating...

2013-11-21 08:26:35

--Company Intends to Proceed Into Follow-On Registration Study in This Indication-- TORONTO, Nov. 21, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC, NASDAQ:ONCY) today announced positive top-line data for the endpoints in its double blinded, randomized clinical study examining REOLYSIN in combination with carboplatin and paclitaxel in patients with second-line platinum-refractory, taxane-naïve head and neck cancers (REO 018). Summary...

2013-11-18 16:29:13

THOUSAND OAKS, Calif., Nov. 18, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced interim overall survival (OS) results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF). Results will be presented today during an oral session at the 2013 Society for Melanoma Research (SMR) Congress, in Philadelphia. At a predefined interim analysis...

2013-11-18 12:29:32

Recognition marks significant industry honor for Genelux proprietary vaccinia-based platform technology SAN DIEGO, Nov. 18, 2013 /PRNewswire/ -- Genelux Corporation, a leader in the emerging field of oncolytic virotherapy, announced today that the Company's lead product candidate, GL-ONC1, has been selected by Elsevier Business Intelligence as one of its 2013 "Top 10 Oncology Projects to Watch." Genelux will present its vaccinia-based proprietary platform technology at the Elsevier...

2013-11-13 08:29:18

WOONSOCKET, R.I., Nov. 13, 2013 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB) has filed a second U.S. patent application concerning methods and formulations to achieve targeted tumor cell death. MCT-485 is a noncoding double stranded micro RNA (miRNA) which has demonstrated oncolytic and immune stimulating activity in in vitro models of hepatocellular carcinoma. MCT-485 is currently being evaluated in animal models of hepatocellular carcinoma. This...

2013-11-07 08:31:16

CALGARY, Nov. 7, 2013 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the quarter ended September 30, 2013. "In recent months we have reported positive data in our squamous cell and non-squamous cell lung clinical trials both in terms of tumour response and survival," said Dr. Brad Thompson, President and CEO of Oncolytics. "On the strength of this reported data, we...

2013-10-28 08:28:06

CALGARY, Oct. 28, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced a poster presentation containing updated efficacy data from a Phase 2 study examining the use of REOLYSIN(®) in combination with carboplatin and paclitaxel in patients with stage IV non-small cell lung cancer (NSCLC) with Kras or EGFR-activated tumors (REO 016) was made at International Association for the Study of Lung Cancer (IASLC). The conference is being held...

2013-10-22 08:31:54

CALGARY, Oct. 22, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that a poster presentation covering progression free survival (PFS) and final tumour response data from its U.S. Phase 2 single arm clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel (REO 021), is being made today at the AACR-NCI-EORTC International...

2013-10-16 09:21:11

Parvoviruses cause no harm in humans, but they can attack and kill cancer cells. Since 1992, scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have been studying these viruses with the aim of developing a viral therapy to treat glioblastomas, a type of aggressively growing brain cancer. A clinical trial has been conducted since 2011 at the Heidelberg University Neurosurgery Hospital to test the safety of treating cancer patients with the parvovirus H-1....

2013-10-02 08:28:44

WOONSOCKET, R.I., Oct. 2, 2013 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB) is pleased to announce the signing of a new sponsored research agreement with Anand Ghanekar, M.D., Ph.D, of the University Health Network's Toronto General Hospital expanding the scope of the research project to evaluate MCT-485 in animal models for the treatment of primary liver cancer. MCT-485 is a noncoding double stranded micro RNA (miRNA) which has demonstrated oncolytic and...